In this patient population, 40 mg BID was the recommended phase 2 dose because it was observed to be safe and efficacious in the phase 1 trial and was predicted to provide asciminib blood concentrations above a preclinically defined inhibitory threshold in all patients with CML-CP without BCR::ABL1T315I [16, 30, 46, 47]. This evidence concerns the gene CP and chronic myelogenous leukemia, BCR-ABL1 positive.